Compare ADMA Biologics Inc (ADMA) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Twilio Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Twilio Inc trades at $254.12 (market cap $38.40B). The key difference: Twilio Inc is far larger — about 17.6× ADMA Biologics Inc's market cap, and Twilio Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | TWLO | |
|---|---|---|
Market Cap | $2.18B | $38.40B |
Sector | Health | Technology |
52-Week High | $20.38 | $255.95 |
52-Week Low | $7.60 | $95.23 |
Enterprise Value | $2.25B | $36.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Twilio (TWLO) trades at $241.28, up 24.89% in 24 hours, near its 52-week high. The stock is in a bullish technical trend with strong support at $228 and resistance at $255. Recent Q2 2026 earnings beat expectations with EPS of $1.47 versus $1.32 expected, and revenue grew 22% year-over-year to $1.5 billion. The company raised full-year 2026 revenue growth guidance to 18%-18.5%.
The outlook is positive with accelerating revenue growth and improving profitability, but risks include high valuation multiples and reliance on continued execution. Analyst consensus is strongly bullish with a $266.31 price target, though the stock's rapid ascent warrants caution near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
